Latest news with #HeartRhythm2025
Reuters
02-05-2025
- Health
- Reuters
Health Rounds: Breast cancer is becoming less deadly for younger women, US study finds
May 2 (Reuters) - (To receive the full newsletter in your inbox for free sign up here) Young U.S. women with breast cancer are not dying from the disease as often as a decade ago, researchers reported, opens new tab at the American Association for Cancer Research 2025, opens new tab meeting in Chicago. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. From 2010 to 2020, breast cancer deaths among women ages 20-49 declined significantly across all breast cancer subtypes and racial and ethnic groups, with marked declines starting after 2016, according to an analysis of data from the national Surveillance, Epidemiology, and End Results registry. Overall, the breast cancer death rate in this age group fell from 9.70 per 100,000 women in 2010 to 1.47/100,000 in 2020. The decline was sharper after 2016, likely due to advancements in treatment options, greater uptake of precision medicine, and expanded access to care and screening in women ages 40-49, study leader Adetunji Toriola of the Washington University School of Medicine in St. Louis said in a statement. While breast cancer mortality declined in every racial and ethnic group, non-Hispanic Black women had the highest rate in both 2010 (16.56/100,000) and 2020 (3.41/100,000). Non-Hispanic white women had the lowest rates in 2010 (9.18/100,000) and 2020 (1.16/100,000). 'We have made tremendous advances in reducing mortality from breast cancer in young women but there are still opportunities for improvements, especially in relation to eliminating disparities,' Toriola said. 'We must continue to perform impactful research to ensure further reduction in breast cancer mortality, including research into understanding the tumor biology and molecular mechanisms driving carcinogenesis and treatment response in younger women.' GLP-1 DRUGS MAY CURB ATRIAL FIBRILLATION GLP-1 drugs that are used to treat diabetes and have become wildly popular for weight loss, may also be useful for controlling the common heart rhythm disorder atrial fibrillation, researchers reported, opens new tab at the Heart Rhythm 2025, opens new tab meeting in San Diego. Researchers looked at more than 2,500 patients with type 2 diabetes, atrial fibrillation and obesity at 170 U.S. Veterans Affairs medical centers. Those who were receiving a GLP-1 drug experienced a 13% reduction in major AF-related events during a median follow-up of three years, compared to patients receiving other medications for their diabetes. AF-related events included hospitalizations for the disorder, need for electroshock therapy to reset the heart rhythm, and ablation procedures to heat heart tissue in order to create scars that interrupt the electrical signals causing the arrhythmia. Researchers did not identify the drugs being taken but common examples of GLP-1 medicines for diabetes include Novo Nordisk's ( opens new tab Ozempic, Rybelsus and Victoza, and Eli Lilly's (LLY.N), opens new tab Mounjaro and Trulicity. Because patients were taking low doses of GLP-1 drugs, rather than higher doses used for weight loss, the results suggest the arrhythmia benefits are independent of any weight-loss benefit, the researchers noted. The study was not designed to prove the GLP-1 drugs caused the reduction in AF events. But study leader Dr. Varun Sundaram of the Louis Stokes Cleveland VA Medical Center and Case Western Reserve University said, "given the growing obesity epidemic and the rising prevalence of atrial fibrillation," it lays the foundation for a new approach to treating AF if larger trials confirm the potential benefits.
Business Insider
26-04-2025
- Health
- Business Insider
Medtronic receives FDA approval for OmniaSecure defibrillation lead
Medtronic (MDT) received U.S. Food and Drug Administration approval for the OmniaSecure defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure Model 3830 pacing lead and delivered via catheter, builds on the Medtronic portfolio of lead solutions designed for precise delivery and placement. The lead connects to an implantable defibrillator, and treats potentially life threatening ventricular tachyarrhythmias, ventricular fibrillation and bradyarrhythmias. As the world's smallest defibrillation lead, the OmniaSecure lead represents a meaningful innovation in electrophysiology, and is indicated for stimulation in the right ventricle for adults and adolescent pediatric patients ages 12 and up, including those with smaller the company is also studying placing the novel, small-diameter OmniaSecure defibrillation lead in the left bundle branch (area, which has the potential to enable physiologic pacing to more closely mimic the heart's natural conduction system. Investigational outcomes of this study were presented at Heart Rhythm 2025 in San Diego. The results from the study demonstrate high defibrillation success of 100% at implant when the lead is implanted in the LBB area. Globally, the OmniaSecure defibrillation lead is investigational for use in LBB area and requires FDA approval in the future. Stay Ahead of the Market:
Malaysian Reserve
26-04-2025
- Health
- Malaysian Reserve
Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead for investigational use in the LBBAP location show high defibrillation success GALWAY, Ireland and SAN DIEGO, April 25, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™ defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure™ Model 3830 pacing lead and delivered via catheter, builds on the Medtronic portfolio of lead solutions designed for precise delivery and placement. The lead connects to an implantable defibrillator, and treats potentially life threatening ventricular tachyarrhythmias, ventricular fibrillation (VT/VF) and bradyarrhythmias. As the world's smallest defibrillation lead (4.7 French, or 1.6mm), the OmniaSecure lead represents a meaningful innovation in electrophysiology, and is indicated for stimulation in the right ventricle for adults and adolescent pediatric patients ages 12 and up, including those with smaller anatomies. Separately, the company is also studying placing the novel, small-diameter OmniaSecure defibrillation lead in the left bundle branch (LBB) area, which has the potential to enable physiologic pacing to more closely mimic the heart's natural conduction system. Investigational outcomes of this study were presented at Heart Rhythm 2025 in San Diego. The results from the study demonstrate high defibrillation success of 100% at implant when the lead is implanted in the LBB area. Globally, the OmniaSecure defibrillation lead is investigational for use in LBB area and requires FDA approval in the future. Implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) are the standard for preventing sudden cardiac death. The ICD/CRT-D connects to a defibrillation lead (insulated electrical wire) that forms the electrical conduit between the device and the heart. The lead senses the heartbeat, and transmits signals to the implanted device, which then delivers therapy to correct or interrupt abnormally fast rhythms. The lead must flex with millions of heart contractions over a lifetime. Existing defibrillation leads are larger in diameter than the OmniaSecure lead. A larger-diameter lead may increase the potential for downstream complications, such as venous occlusion or tricuspid valve regurgitation. 'FDA approval for the OmniaSecure defibrillation lead furthers our ability to offer physicians and patients a transvenous solution designed to be smaller to help minimize complications−including vascular complications and valve interaction−with strong, reliable lead durability. We engineered the OmniaSecure lead based on the trusted SelectSecure Model 3830 pacing lead, which has been the lead of choice for many physicians for more than 20 years,' said Alan Cheng, M.D., chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. 'This milestone underscores our commitment to driving clinical innovations that help patients today while paving the way for future innovations that will usher in the next era of electrophysiology.' Previously, researchers presented late breaking data from the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivotal Trial showing the OmniaSecure defibrillation lead met its primary safety and effectiveness endpoints and exceeded prespecified performance goals when placed within the right ventricle. The results were presented during Heart Rhythm 2024, simultaneously published in Heart Rhythm, and are the basis of FDA approval for the traditional right ventricular lead placement indication. Late-Breaking LEADR LBBAP Results Presented at Heart Rhythm 2025 Researchers presented late-breaking results at Heart Rhythm 2025 for the LEADR LBBAP (Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing) study that showed the OmniaSecure defibrillation lead demonstrated high defibrillation success when placed in the LBB area for patients indicated for an ICD or CRT-D. Placing the defibrillation lead in the LBB area is being evaluated as an alternative to right ventricular stimulation for sensing, pacing, cardioversion and defibrillation. Defibrillation testing conducted in 162 patients at device implantation was successful in 100% of cases, with the study meeting the prespecified efficacy goal of 88%. Of the first 193 patients implanted in the study, the OmniaSecure lead was successfully implanted per protocol in 95.8% of the procedures as reported by physician investigators. There were no procedure-related major complications such as early helix or lead fracture, system revision, or death. 'The left bundle branch area is emerging as an option for more physiologic pacing for patients who receive an ICD or CRT-D to treat dangerous heart rhythms,' said Pugazhendhi Vijayaraman, M.D., cardiac electrophysiologist at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa., who presented the data at the meeting. 'The option to place a lead in the left bundle branch area may provide for physiologic pacing by engaging the heart's natural conduction system. These positive preliminary results for the LEADR LBBAP study are encouraging and highlight the potential versatility of the OmniaSecure defibrillation lead.' The LEADR LBBAP trial is a global, prospective, non-randomized, multi-center study. The study has enrolled approximately 300 patients at 24 sites in 11 countries in North America, Europe, Asia and Australia. Patients enrolled in the study indicated for an ICD are being followed out to 3 months while patients indicated for CRT-D are being followed out to 6 months post-implant. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit and follow Medtronic on LinkedIn. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. Contacts: Joey LomickyPublic Relations+1-763-526-2494 Ryan WeispfenningInvestor Relations+1-763-505-4626
Yahoo
23-04-2025
- Business
- Yahoo
Kestra Medical Technologies to Showcase Innovation in Sudden Cardiac Arrest Protection and Recovery at Heart Rhythm 2025
Company to spotlight ASSURE WCD performance and expanded clinical applications KIRKLAND, Wash., April 23, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) ('Kestra'), a wearable medical device and digital healthcare company, announced today it will exhibit at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society (HRS), taking place April 24-27 at the San Diego Convention Center. This marks Kestra's first major industry showcase following its successful IPO earlier this year. Kestra will debut an immersive in-booth experience designed to bring the ASSURE® system to life—demonstrating how this innovative technology is redefining protection for patients at risk of sudden cardiac arrest. By combining lifesaving defibrillation therapy with intuitive, intelligent, and connected diagnostic and patient support capabilities, the ASSURE system is a key part of a broader vision for a holistic cardiac care ecosystem that supports patients and providers across the recovery journey. 'Our presence at Heart Rhythm 2025 comes at a pivotal time for Kestra,' said Brian Webster, President and Chief Executive Officer of Kestra. 'Following our IPO, we're moving forward with increasing momentum—and this year's HRS meeting is an opportunity to demonstrate how the ASSURE system goes beyond protection to offer a smarter, more connected recovery experience for both patients and care teams.' In addition to exhibiting, Kestra will also present new real-world clinical data highlighting the impact of the ASSURE system. Kestra is also proud to sponsor the Women in EP Luncheon for the fourth consecutive year—underscoring its ongoing commitment to leadership, innovation, and equity in cardiovascular care. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit Media contactRhiannon Investor contactNeil in to access your portfolio
Business Wire
22-04-2025
- Business
- Business Wire
CardioFocus to Showcase PFA Portfolio at Heart Rhythm 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, is excited to announce its featured presence at Heart Rhythm 2025 in San Diego, where the company will showcase the latest advancements and clinical progress in pulsed field ablation (PFA) technology for the treatment of atrial fibrillation. 'Our message is clear this year: We're solving the PFA equation of waveform plus contact to elevate patient outcomes,' said Steve Ogilvie, CEO of CardioFocus. Share CardioFocus will kick off the week at the Stanford Biodesign New Arrhythmia Technologies Retreat on Wednesday, April 23, at The Westin San Diego. Dr. Atul Verma will speak at 2:50 PM, highlighting the unique PFA approach CardioFocus is pioneering. 'We're honored to be featured at this retreat,' said Steve Ogilvie, CEO of CardioFocus. 'It's the perfect stage to elaborate on the unique science driving our PFA innovation.' The momentum continues on Thursday, April 24, with the PFA Live Case Summit 2025, where the company's next-generation OptiShot™ PFA Balloon Catheter will be showcased in a live, first-in-human case from the VISION AF trial. This live case broadcasted from Homolka Hospital in Prague, Czech Republic, will highlight how OptiShot combines advanced waveform technology and circumferential contact with an ultra-compliant balloon design to deliver consistent pulmonary vein isolation (PVI). OptiShot is one of several different approaches that the company is taking in its portfolio approach to PFA, including focal (currently available in the EU & UK), a large focal deca-spline mini basket called QuickShot™ Nav (under first-in-human clinical investigation in the Quick AF trial), and new generator, CardioWave™ (planned for future investigation). From April 25–27, at the Heart Rhythm 2025 conference at the San Diego Convention Center, CardioFocus invites attendees to explore its PFA science at Booth 1328 and in our Tech Suite (TS855), which will host both scheduled appointments and walk-in hours. Visitors will get an inside look at the company's development philosophy to combine waveform, contact, and catheter design and how diligent pre-clinical research has delivered clinical success with PFA. 'Our message is clear this year: We're solving the PFA equation of waveform plus contact to elevate patient outcomes,' said Ogilvie. 'We're excited to engage, learn, and lead alongside the EP community.' Centauri is not approved for sale in the United States. The OptiShot™ PFA Balloon System and QuickShot™ Nav is investigational and not approved for commercial use.
